Oric Pharmaceuticals, Inc. — Director's Dealing 2021

Mar 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2021-03-24

Reporting Person: GORDON CARL L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-24	Common Stock	S	32959	$24.80	Disposed	2395334	Indirect
2021-03-25	Common Stock	S	51523	$24.70	Disposed	2343811	Indirect
2021-03-26	Common Stock	S	27816	$23.88	Disposed	2315995	Indirect

Footnotes

F1: These shares of the Issuer's common stock were sold in a block order at a price of $24.80 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VI, LP ("OPI VI").

F2: These shares of the Issuer's common stock are held of record by OPI VI. OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F3: Each of the Reporting Person, OrbiMed Advisors, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VI is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4: These shares of the Issuer's common stock were sold in a block order at a price of $24.70 pursuant to a Rule 10b5-1 trading plan established by OPI VI.

F5: These shares of the Issuer's common stock were sold in a block order at a price of $23.88 pursuant to a Rule 10b5-1 trading plan established by OPI VI.